Please login to the form below

Not currently logged in
Email:
Password:

IBD

This page shows the latest IBD news and features for those working in and with pharma, biotech and healthcare.

PureTech adds potential IBD therapeutic to pipeline after buying out Alivio Therapeutics

PureTech adds potential IBD therapeutic to pipeline after buying out Alivio Therapeutics

Alivio is developing therapeutic candidates for a number of inflammatory disorders, including inflammatory bowel disease (IBD). ... Among these candidates is LYT-500, an orally-administered therapeutic candidate currently in development for the treatment

Latest news

More from news
Approximately 11 fully matching, plus 33 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    With IBD widely considered an ‘invisible disease’, patients cannot afford to be pushed into the background any longer. ... and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead.

  • Gut instincts lead Takeda to GI pipeline success Gut instincts lead Takeda to GI pipeline success

    It has been a game changer for IBD patients and the EMA decision means that they have greater choice. ... Projects that address gut inflammation beyond IBD are focused on coeliac disease, acute pancreatitis and short bowel syndrome.

  • Case study: Logic IBD Nurse Education Day and Recognition Event Case study: Logic IBD Nurse Education Day and Recognition Event

    The solution was a dual-aspect meeting: The ‘LOGIC IBD Nurse Education Day and Recognition Event’. ... IBD nurses had limited support with personal development and raising their profile within their hospital/Trust.

  • Case study: IBD Registry Roadshow Case study: IBD Registry Roadshow

    It was originally planned to run alongside a successful national IBD Audit programme managed by the Royal College of Physicians (RCP). ... In 2015 NHS England announced it was pulling the Audit funding and recommended that future audits be incorporated

  • Deal Watch February 2017 Deal Watch February 2017

    The deal also includes a licence to AKB-5169 (formerly JNJ5169), an oral, preclinical stage compound for inflammatory bowel disease (IBD).  . ... Joint venture. 286.3. Janssen/ Akebia Therapeutics. HIF-targeting candidates inc AKB-5169 for IBD (pc)

More from intelligence
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 3 fully matching, plus 19 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Stick or Twist? Healthcare brands in a (post) COVID-19 world
...
Stick or twist? Looking at the patient experience as we emerge from the COVID pandemic
...
Lockdown entertainment or healthcare revolution? The role of video games in healthcare
...